Emerging studies suggest this peptide, a dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , may offer a notable step forward for obesity management . Preliminary patient tests have demonstrated impressive decreases in visceral tissue, potentially surpassing existing body composition medications . Nevertheless ,